Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Hodgkin Disease 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Teratoma 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multi-centric Castleman's Disease 1Malignant mesenchymal tumor 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphadenopathy 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia 1Hematologic Neoplasms 1HIV Infections 1Glioma 1Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 13Temozolomide 9Specimen Handling 9X-Rays 6Biopsy 6Nuclear Medicine Department, Hospital 5erdafitinib 4Phantoms, Imaging 4ulixertinib 3trametinib 3dabrafenib 3Radiotherapy 3Radiation 3tipifarnib 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2ensartinib 2binimetinib 2Surgical Procedures, Operative 2Nivolumab 2veliparib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1temsirolimus 1tazemetostat 1selinexor 1sapanisertib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Filgrastim × 30 days × Clear all
NCT06528691 2026-05-13

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

St. Jude Children's Research Hospital

Phase 2 Recruiting
52 enrolled
CNS

Glioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡